Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Phase II NCT06937931

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults — Recruiting • Phase II • Neurology • NCT06937931.

📅 06 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Phase II
NCT ID
NCT06937931
Start
2025-06-30
Completion
2027-03-26
ClinicaliQ Trial Snapshot
  • A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults — Recruiting • Phase II • Neurology • NCT06937931.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults. CD can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. CD is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role. The usual treatment…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Mirdametinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years
Neurology · 16 Sep 2026
Mirdametinib is indicated for symptomatic and inoperable plexiform neurofibromas in children aged 2-17 years with neurofibromatosis type 1 (NF1); confirm diagnosis and…
View guideline →
Guideline
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal)
Neurology · 07 May 2026
Oxybutynin is effective for neurogenic detrusor overactivity in patients aged 6+ years with spinal cord injury or spina bifida—consider as first-line antimuscarinic…
View guideline →
Guideline
2022 EAN/EFNS Guidelines on Dementia Diagnosis and Management
Neurology · 30 Mar 2026
This EAN guideline addresses 2022 EAN/EFNS Guidelines on Dementia Diagnosis and Management in Neurology. Use it to review current recommendation wording, eligibility…
View guideline →
Guideline
2023 EAN Guidelines on the Management of Multiple Sclerosis
Neurology · 30 Mar 2026
This EAN guideline addresses 2023 EAN Guidelines on the Management of Multiple Sclerosis in Neurology. Use it to review current recommendation wording,…
View guideline →
Guideline
Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment
Neurology · 01 Oct 2026
AI-assisted EEG interpretation software can support clinicians in identifying abnormalities suggestive of epilepsy, but should complement rather than replace expert clinical review—use…
View guideline →
Clinical Brief
Nobel Prize awarded for revealing inner workings of the brain
Neurology · BBC Health · 05 Oct 2026
Karl Deisseroth, Peter Hegemann, and Georg Nagel have been awarded the Nobel Prize for developing optogenetics, a technique enabling precise control of…
View brief →